Hızlı Erişim


Bu Dergi DOI ve Crosscheck üyesidir


Abstract


MANAGEMENT OF VENOUS SYSTEM DISEASES DURING THE PANDEMIC PERIOD

Venous insufficiency and deep vein thrombosis (DVT) are the main venous system diseases. Although deep vein thrombosis (DVT) can lead to serious complications and even death, it is a treatable disease. Today, both DVT and pulmonary embolism (PE) are referred to by the common name of venous thromboembolism (VTE). Although COVID-19 mainly affects the respiratory system, it also tends to damage many organs and develop VTE due to its prothrombotic course. In patients recovering from COVID-19, the venous system is adversely affected due to the prothrombotic course of the disease and immobility. In our study, venous system diseases and their treatments after COVID-19 disease were reviewed. Thirty of the patients who applied to our hospital with the preliminary diagnosis of venous insufficiency after recovering from COVID-19 were included in our study. The physical examination findings and laboratory parameters of the patients were retrospectively reviewed. In all cases, besides routine laboratory tests, radiological and vascular Doppler ultrasonographic examinations were also performed. Results Of the 30 patients included in the study, 11 (36.6%) were male and 19 (63.3%) were female. Their ages ranged from 30 to 79 years, with a mean age of 59.4±12.77 years. Venous insufficiency was detected in all patients in venous Doppler ultrasonographic examination. In addition, DVT was also detected in four cases. Fifteen (50%) of our patients were hypertensive. Diabetes mellitus was also present in five of the hypertensive patients. Combined diosmin and hesperidin treatment may be preferred in cases of venous insufficiency developing after COVID-19. Since no adverse effects of warfarin have been observed in severe COVID-19 disease, it can be used safely in DVT cases that develop after the treatment of COVID-19.



Keywords
Pandemic, Venous Insufficiency, Thrombosis, Anticoagulation.



Kaynakça 1. Abed HS, Kilborn MJ, Chen V, Sy RW. Reversal Agents in the Era of NOACs. J Atr Fibrillation. 2017;10(4):1634. doi: 10.4022/jafib.1634. 2. Brandão GMS, Cândido RCF, Rollo HA, Sobreira ML, Junqueira DR. Direct oral anticoagulants for treatment of deep vein thrombosis: overview of systematic reviews. J Vasc Bras. 2018;17(4):310-317. doi: 10.1590/1677-5449.005518. 3. Canbolat İP, Belen E, Sinan ÜY, Başkurt M. Comparative follow-up results of novel oral anticoagulants in daily practice. FNG & Bilim Tıp Dergisi 2017;3(1):15-18. 4. Candido S, Lumera G, Barcellona G, Vetri D, Tumino E, Platania I, et al. Direct oral anticoagulant treatment of deep vein thrombosis reduces IL-6 expression in peripheral mono-nuclear blood cells. Exp Ther Med. 2020;20(6):237. doi: 10.3892/etm.2020.9367. 5. Carfora V, Spiniello G, Ricciolino R, Di Mauro M, Migliaccio MG, Mottola FF, Verde N, Coppola N; Vanvitelli COVID-19 group. Anticoagulant treatment in COVID-19: a narrative review. J Thromb Thrombolysis. 2021;51(3):642-648. doi: 10.1007/s11239-020-02242-0. PMID: 32809158; PMCID: PMC7432456. 6. Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020 doi: 10.1055/s-0040-1712097. 7. Flaczyk, A, Rosovsky, RP, Reed, CT, et al. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: Implications for clinical practice and future investigations. Crit Care 2020; 24: 559. 8. Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Med Hypotheses. 2020;144:109957. doi: 10.1016/j.mehy.2020.109957. 9. Ho FK, Man KKS, Toschner M, Celis-Morales C, Wong ICK, Sattar Net al. COVID-19 infection and subsequent thromboembolism: A self-controlled case series analysis of a population cohort: https://doi.org/10.1101/2021.02.02.21251043. 10. Kajy M, Mathew A, Ramappa P. Treatment Failures of Direct Oral Anticoagulants. Am J Ther. 2021;28(1):e87-e95. 11. Köksal Ö, Durak VA. Emergency Service Management of Bleeding Due to New Generation Oral Anticoagulants.Anatolian Journal of Emergency Medicine 2020;3(2); 62-65. 12. Lähteenmäki J, Vuorinen AL, Pajula J, Harno K, Lehto M, Niemi M, van Gils M. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharmacol Ther. 2021;110(3):768-776. doi: 10.1002/cpt.2316. 13. Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis. Hamostaseologie. 2020;40(3):264-269. doi: 10.1055/a-1178-3551. 14. Laslo CL, Bacalbasa N, Stanescu AMA, Carsote M, Bungau S, Rus M, Bratu OG, Diaconu CC. New oral anticoagulants - possible extension to other indications (Review). Exp Ther Med. 2020;20(3):2401-2405. doi: 10.3892/etm.2020.8713. 15. Levi M, van der Poll T and Büller HR: Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698–2704. 2004. 15. Mekaj YH, Mekaj AY, Duci SB and Miftari EI: New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977. 17. OpenSAFELY Collaborative, Wong AYS, Tomlinson LA, Brown JP, Elson W, Walker AJ, Schultze A, et al. Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. J Hematol Oncol. 2021;14(1):172. doi: 10.1186/s13045-021-01185-0. 18. Özbalcı D. Anticaogulant therapy in Covid-19. Med J SDU 2021;(özel sayı-1):37-45. 19. Petca A, Petca RC, Zvanca M, Maru N, Mastalier B and Dogaroiu C: Fetal death from ruptured vasa previa: A tragic event in the ultrasonographic era. Rev Med Leg. 2019;27:43–46. 20. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S, Lille ICU Haemostasis COVID-19 group Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020 doi: 10.1161/CIRCULATIONAHA.120.047430. 21. Poveda-Jaramillo R. Coronavirus disease 2019-induced hypercoagulability and its clinical implications. Asian Cardiovasc Thorac Ann. 2021:2184923211069185. doi: 10.1177/02184923211069185. 22. Soyer NA. Akılcı ilaç kullanımı: Yeni nesil oral antikoagülanlar. Ege Med J 2021;60(suppl):32-25. 23. Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switch from warfarin to NOACs? Intern Emerg Med. 2016;11(3):289-93. doi: 10.1007/s11739-016-1411-0. 24. Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995). 2020 Oct;48(4):169-179. doi: 10.1080/21548331.2020.1772639. 25. Zhang Y, Zhang Z, Wei R, Miao X, Sun S, Liang G, et al: IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler Thromb Vasc Biol. 2020;40:323–334.

Gelişmiş Arama


Duyurular

    ***********************

    mail mail mail mail mail

    Dergimizin Aralık sayısı 

    (25.12.2021)

    yayınlanmıştır.

    mail mail mail mail mail

    mail mail mail mail mail

    25 Mayıs 2022 tarihinde yayınlanacak sayımız için değerlendirilmek üzere 20 Nisan 2022 tarihine kadar makalenizi sisteme yükleyebilirsiniz!

    mail mail mail mail mail

     



Adres :Göztepe Mah., Beykoz, İstanbul/TURKEY
Telefon : Whatsapp: +90 555 005 92 85 Faks :+90 216 606 32 75
Eposta :info@euroasiajournal.org

Web Yazılım & Programlama Han Yazılım Bilişim Hizmetleri